1. Trial Selection Process
Jingjing Zhang, et al. JAMA. 2006;296:

2. Included Trials of Rofecoxib*
Jingjing Zhang, et al. JAMA. 2006;296:

3. Included Trials of Celecoxib*
Jingjing Zhang, et al. JAMA. 2006;296:

4. Included Trials of Valdecoxib and Parecoxib*
Jingjing Zhang, et al. JAMA. 2006;296:

5. Included Trials of Etoricoxib and Lumiracoxib
Jingjing Zhang, et al. JAMA. 2006;296:

6. Descriptive Characteristics of Included Randomized Double-Blind Clinical Trials of Cyclooxygenase 2 Inhibitors
Jingjing Zhang, et al. JAMA. 2006;296:

7. Number of Arrhythmia Events by Reported Subtypes
Jingjing Zhang, et al. JAMA. 2006;296:

8. Overall Relative Risks of Renal and Arrhythmia Events, Cyclooxygenase 2 Inhibitors vs Controls
Jingjing Zhang, et al. JAMA. 2006;296:

9. Relative Risk of Composite Renal Events (Renal Dysfunction, Peripheral Edema, Hypertension) by COX-2 Inhibitors, Meta-Regression Stratified by Study Characteristics
Jingjing Zhang, et al. JAMA. 2006;296:

10. Time-Cumulative Analysis of Rofecoxib and Risk of Renal and Arrhythmia Events
Sensitivity analyses of the 9 trials with participants (10126 drug, control group) and 15 arrhythmia events (13 drug, 2 control group) without half-integer correction using sparse-events exact methods:
Fisher exact test P =.004, and Mantel-Haenszel pooled relative risk 6.52 (95% CI, ; P=.004)
Jingjing Zhang, et al. JAMA. 2006;296: